Taysha Gene Therapies Inc

Healthcare · Biotechnology · —

4.40$ +0.0% vs. previous close Closing price · As of: Oct 8, 2026

Statements

Balance Sheet

Taysha Gene Therapies Inc (TSHA) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 470 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size %

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet TSHA
Line item	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Total Assets	–	–	11	279	259	243	242	241	214	166	142	111	126	102	82	196	173	153	200	180	160	138	333	317	343	300	470
Current Assets	–	11	11	279	258	240	207	197	160	107	77	43	96	72	54	172	150	131	178	162	142	121	316	300	325	282	461
Cash	–	–	11	279	251	229	197	189	149	97	66	34	88	63	45	164	144	124	173	158	139	117	313	297	320	277	455
Cash & Short-Term Investments	–	–	11	279	251	229	197	189	149	97	66	34	88	63	45	164	144	124	173	158	139	117	313	297	320	277	455
Property, Plant & Equipment	–	0.0	0.0	0.0	0.3	2.5	34	41	51	55	61	64	26	15	14	–	–	–	–	–	–	–	–	–	–	–	–
Total Liabilities	–	–	20	12	7.6	20	55	101	119	115	110	100	125	117	119	245	98	99	92	91	89	83	85	98	96	88	83
Current Liabilities	–	20	20	12	7.1	19	28	43	52	49	43	33	63	54	51	180	37	39	34	29	26	23	25	29	27	20	26
Short-Term Debt	–	–	17	–	–	–	–	–	–	–	–	–	1.5	1.8	1.6	1.5	1.6	1.7	1.8	1.8	1.9	1.8	1.7	1.7	–	–	–
Accounts Payable	–	1.3	1.3	8.8	2.0	4.1	6.4	22	22	22	24	15	11	9.0	11	7.5	6.4	10	8.7	4.9	3.6	4.3	7.7	5.4	6.3	4.6	9.2
Long-Term Debt	–	–	–	–	–	–	–	28	37	37	38	38	38	38	38	39	41	41	38	43	44	42	41	51	50	49	49
Shareholders' Equity	–	-0.1	-8.8	268	251	223	186	140	95	51	33	11	0.9	-15	-37	-49	75	54	109	89	72	55	249	219	247	212	387
Retained Earnings	–	-28	-28	-43	-61	-93	-134	-185	-236	-286	-320	-346	-401	-419	-444	-561	-513	-537	-558	-584	-602	-624	-651	-683	-711	-754	-800
Shares Outstanding	15	15	35	12	38	37	37	38	38	38	40	41	56	63	64	126	187	231	233	268	205	269	298	353	320	367	369

Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Balance Sheet

Cookie settings